1D' Amato RJ,Louqhman MS,Flynn E,et al. Thalidomide is an inhibitor of angiogenesis [ J]. Proc Nail Acad Sci USA, 1994,91 (9) : 4082 - 4085.
2Komorowski J,Jerczynska H,Siejka A,et al. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA. hy 926 cells [ J ]. Life Sciences,2006,78 ( 22 ) : 2558 - 2563.
3Tamilarasan KP, Kolluru GK, Rajaram M. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells [ J ]. BMC Cell Biol,2006,7 : 17.
4Yasui K, Kobayashi N, Yamazaki T, etal. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation [ J ]. Curr Pharm Des, 2005,11 ( 3 ) : 395 -401.
5Teo SK. Properties of thalidomide and its analogues implications for anticancer therapy [J]. AAPS J,2005,7 ( 1 ) :14 - 19.
6Teo, Steve K, Stifling. Thalidomide as a novel therapeutic agent:new uses for an old product [ J ]. Drug Discovery Today, 2005, 10 (2) :107 -114.
7Haslett PA,Roche P,Buflin CR,et al. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation [ J ]. J Infect Dec, 2005, 192 (12) :2045 -2053.
8Du GJ, Lin HH, Xu QT, et al. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis [J]. Vascul Pharmacol,2005,43(2) : 112 - 119.
9Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus efficacy and safety of different therapeutic regimens [ J ]. Am J Med, 2005,118 (3) :246 -250.
10Gardner-Medwin JM, Smith N J, Powell ILl. Clinical experience with thalidomide in the Management of severe oral and genital ulceration in conditions such as Behcet disease: use of neurophysiological studies to detect thalidomide neuropathy [ J ]. Ann Rheum Dis. 1994.53 ( 12 ) : 828 - 832.
